By Mark E. Neumann
AWAK Technologies has received a breakthrough device designation from the FDA for its progression prediction model directed at patients with chronic kidney disease, according to a press release. Read the article in Healio.
By David Statman
PHILADELPHIA — The association between obesity and chronic kidney disease may be partially explained by inflammatory cytokines and high levels of leptin, according to data from a study presented at ASN Kidney Week.
The data showed that inflammatory and proinflammatory mediators were highest in obese patients, with maximum aberrations occurring in obese patients with CKD, suggesting a potential link. Read the article in Healio.
When Is It Time to Talk About Kidney Transplantation?
By Matthew A. Sparks, MD; Samira S. Farouk, MD, MSCR
This transcript has been edited for clarity.
Matthew A. Sparks, MD: I’m Dr Matthew Sparks. Welcome to Medscape’s InDiscussion series on chronic kidney disease. Today we’ll be discussing kidney transplantation with my guest, Dr Samira Farouk. Dr Farouk is an associate professor of medicine and medical education and a transplant nephrologist at the Icahn School of Medicine at Mount Sinai. She is also the associate program director of the fellowship program. Check out the complete podcast in Medscape.
By Mark E. Neumann
One goal of the Advancing American Kidney Health initiative, which was launched in 2019, was to significantly increase the number of kidney transplants.
The way to do that, according to CMS at the time, was to intervene early and slow chronic kidney disease progression so preemptive transplants could be performed, allowing patients to forgo dialysis.
Read the full story in Healio.
By Shawn M. Carter
While SGLT2 inhibitors are often associated with bone and mineral metabolism irregularities, it remains unclear if these are linked to higher fracture risk in patients with chronic kidney disease, according to recently published research. Read the full article in Healio.
By Shannon Firth
Physicians and advocates explored ways to improve access to clinical trials, dialysis, and transplants for racial and ethnic minorities with chronic kidney disease during a webinaropens in a new tab or window hosted by U.S. News & World Report and sponsored by the American Kidney Fund (AKF).
When the COVID-19 pandemic struck, people with chronic kidney disease, particularly those in kidney failure, could not isolate the way other people could because they needed to go to dialysis or other medical appointments, explained LaVarne Burton, president and CEO of the AKF.
Read the full article in MedPage Today.
By Dr. Priyom Bose, PhD
Around 10% of the global population is affected by chronic kidney disease (CKD). The risk of CKD progressing into end-stage renal disease (ESRD) is exceptionally high, which requires dialysis or kidney transplantation. At present, there is no effective treatment for CKD is available. Hence, there is an urgent need to uncover the underlying pathological mechanisms of CKD to help formulate effective treatment strategies to prevent and cure the disease. A recent Nature Communications study suggested that DNA-PKcs could be a potential target for treating CKD. Read more in News Medical Life Sciences.
by Leigh MacMillan
Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury. The findings, reported in The Journal of Clinical Investigation, identify a novel signaling pathway as a therapeutic target in chronic kidney disease progression. Read more from the VUMC Reporter.
The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a post hoc analysis of the DAPA-CKD trial. Read more in Healio.
Based on both clinic and ambulatory blood pressure, children with chronic kidney disease are more likely to be grouped as hypertensive when using the American Academy of Pediatrics 2017 clinical practice guidelines vs. its 2004 guidelines.
Read the full story in Healio.